Search

Efalizumab

The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]

Promethazine

[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]

Aminophenazone

The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942]

Atibuclimab

Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

Hematin

1-Dodecanol

(From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)

Rintodestrant

Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).

Taragarestrant

Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).

Ibrutinib

[L12228] Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.[L43020] … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in

Afamitresgene autoleucel

[L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial